Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 4:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 113 matching trials from the live ClinicalTrials.gov search.
Conditions
Intracranial Neoplasm
Interventions
Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Gadobenate Dimeglumine, Gadoterate Meglumine, Magnetic Resonance Imaging
Device · Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Intracranial Venous Blood, Brain Cancers, Liquid Biopsy, Evaluate the Safety
Interventions
blood sampling
Diagnostic Test
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Conditions
Brain Injuries, Traumatic, Spinal Cord Trauma, Intracranial Neoplasm
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Acute Brain Injury, Traumatic Brain Injury, Intracranial Hemorrhage, Hydrocephalus, Stroke, Brain Neoplasm, Hypoxia-Ischemia, Brain
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
2 Years to 17 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Benign Centrally-Located Intracranial Tumors
Interventions
ExAblate 4000 System
Device
Lead sponsor
InSightec
Industry
Eligibility
5 Years to 22 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Miami, Florida • Houston, Texas
Conditions
Recurrent Meningioma
Interventions
Actinium Ac 225 DOTATATE RYZ101, Biospecimen Collection, Computed Tomography, Echocardiography Test, Gallium Ga 68-DOTATATE, L-lysine/L-arginine-containing Amino Acid, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography, Somatostatin Receptor Positron Emission Tomography
Drug · Procedure · Radiation
Lead sponsor
Joshua Palmer
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Brain Tumor, Central Nervous System Tumors, Childhood Germ Cell Tumor
Interventions
carboplatin, etoposide, ifosfamide, thiotepa, adjuvant therapy, conventional surgery, neoadjuvant therapy, peripheral blood stem cell transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 24 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
90
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 79 more
Conditions
Intracranial Metastatic Disease From Any Solid Malignancy
Interventions
Ethos Therapy
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
St Louis, Missouri
Recruiting Phase 1 Interventional

ABY-029 Glioma Trial

NCT07063693
Conditions
Intracranial Tumor
Interventions
ABY-029
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Lebanon, New Hampshire
Conditions
Alzheimer Disease, Mild Dementia, Mild Cognitive Impairment, Dementia, Dementia, Vascular, Dementia Alzheimers, Dementia, Mild, Dementia, Mixed, Dementia of Alzheimer Type
Interventions
Virtual Kitchen Training
Behavioral
Lead sponsor
Temple University
Other
Eligibility
65 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Intracranial Neoplasm
Interventions
Fluorethyltyrosine (18-F), Positron Emission Tomography (PET)
Drug · Procedure
Lead sponsor
Thomas Hope
Other
Eligibility
4 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Francisco, California
Conditions
Glioblastoma Multiforme
Interventions
Bevacizumab
Drug
Lead sponsor
Global Neurosciences Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Arteriovenous Malformations, Cavernous Angiomas, Brain Aneurysms
Interventions
Doxycycline or Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Francisco, California
Conditions
Cerebrovascular Disorders, Intracranial Neoplasms
Interventions
Fluorescein Sodium
Drug
Lead sponsor
AdventHealth
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Orlando, Florida
Conditions
Cerebral Vein Thrombosis, Deep Vein Thrombosis, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Pulmonary Embolism, Splanchnic Vein Thrombosis
Interventions
Apixaban
Drug
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
32
States / cities
Scottsdale, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 27 more
Conditions
Cerebral Vein Thrombosis, Deep Vein Thrombosis, Gonadal Thrombosis, Hepatic Thrombosis, Malignant Neoplasm, Mesenteric Thrombosis, Metastatic Malignant Neoplasm, Portal Vein Thrombosis, Pulmonary Embolism, Renal Vein Thrombosis, Splenic Thrombosis, Venous Thromboembolism
Interventions
Apixaban, Dalteparin, Questionnaire Administration
Drug · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
18
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Evanston, Illinois + 15 more
Conditions
Melanoma, Renal Cell Carcinoma, Brain Metastases, PD1/PD-L1 Experienced, Pembrolizumab, Lenvatinib, Metastatic Melanoma
Interventions
Pembrolizumab, Lenvatinib
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Brain Tumor, Stroke, Acute, Brain Aneurysm, Intracranial Arteriovenous Malformations, Carotid Stenosis, Cavernous Sinus Thrombosis
Interventions
Transradial approach
Device
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Newark, New Jersey
Conditions
Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain
Interventions
Dual-Energy Computed Tomography
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Houston, Texas
Conditions
Healthy Subject, Intracranial Neoplasm, Glioblastoma
Interventions
Fluorine F 18 DASA-23, Positron Emission Tomography
Drug · Procedure
Lead sponsor
Guido A. Davidzon, MD, SM
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Metastatic Breast Cancer With Intracranial Metastases
Interventions
cabazitaxel, lapatinib
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Fort Myers, Florida • St. Petersburg, Florida • Cincinnati, Ohio + 1 more
Conditions
Intracranial Neoplasms, Neoplasm Metastasis
Interventions
2-deoxyglucose (2DG)
Drug
Lead sponsor
University of Iowa
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation, BRAF V600E, BRAF V600 Mutation, BRAF Mutation-Related Tumors, BRAF, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, Recurrent Lung Cancer, Recurrent Lung Non-Small Cell Carcinoma, NSCLC, Solid Tumor, Solid Carcinoma, KRAS G12D, KRAS G12V, KRAS Mutation-Related Tumors, NRAS Gene Mutation, Thyroid Cancer, Thyroid Carcinoma, Colorectal Cancer, Colorectal Carcinoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Brain Metastases, Recurrent NSCLC, KRAS G13C, Acquired Resistance to KRAS G12C Inhibitor, KRAS G12A, KRAS G12F, KRAS G12R, KRAS G13D
Interventions
S241656, FOLFOX6/FOLFOX7, FOLFIRI, Cetuximab, Panitumumab, Trametinib, Pembrolizumab
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
18 Years and older
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
21
States / cities
Gilbert, Arizona • Los Angeles, California • San Francisco, California + 15 more
Conditions
Brain Tumor, Glioblastoma
Interventions
MRI/MRS Scan
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Houston, Texas